Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia

Cancer Research and Treatment

Volumn 49, Issue 2, 2017, Pages 548-552

  Lutz, Mathias ^a   Schulze, Arik B ^a   Rebber, Elisabeth ^a,b   Wiebe, Stefanie ^a   Zoubi, Tarek ^a   Grauer, Oliver M ^a   Keßler, Torsten ^a   Kerkhoff, Andrea ^a   Lenz, Georg ^a,c   Berdel, Wolfgang E ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b MarienHospital Osnabruck   (Germany)

^c Cells in Motion ^*  (Germany)

Author keywords

B Cell chronic lymphocytic leukemia; Ibrutinib; JC virus; Progressive multifocal leukoencephalopathy; Rituximab

Indexed keywords

CLARITHROMYCIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUDARABINE; IBRUTINIB; IMMUNOGLOBULIN; MEFLOQUINE; MEROPENEM; MIRTAZAPINE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE; RITUXIMAB; VANCOMYCIN; VIRUS DNA; ANTINEOPLASTIC AGENT; MIANSERIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; ANTIBIOTIC THERAPY; ARTICLE; B LYMPHOCYTE; BONE MARROW DEPRESSION; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; JC VIRUS; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SYMPTOMATOLOGY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BRAIN; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; FATALITY; MALE; MULTIMODAL IMAGING; PATHOLOGY; PROCEDURES;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; DISEASE PROGRESSION; FATAL OUTCOME; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MEFLOQUINE; MIANSERIN; MULTIMODAL IMAGING; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES;

EID: 85017342690     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2016.110     Document Type: Article

References (15)

1. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25:471-506.
2. Honce JM, Nagae L, Nyberg E. Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities. Mult Scler Int. 2015;2015:809252.
3. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain. 1958;81:93-111.
4. Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect. 2011;17:1776-80.
5. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870-80.
6. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834-40.
7. Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol. 2014;3:4.
8. Tucker DL, Rule SA. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Ther Clin Risk Manag. 2015;11:979-90.
9. Epperla N, Medina-Flores R, Mazza JJ, Yale SH. Mirtazapine and mefloquine therapy for non-AIDS-related progressive multifocal leukoencephalopathy. WMJ. 2014;113:242-5.
10. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med. 1998;338:1345-51.
11. Marra CM, Rajicic N, Barker DE, Cohen BA, Clifford D, Donovan Post MJ, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16: 1791-7.
12. Clifford DB, Nath A, Cinque P, Brew BJ, Zivadinov R, Gorelik L, et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol. 2013;19:351-8.
13. Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A, et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med. 2014;370: 486-8.
14. Lane MA, Renga V, Pachner AR, Cohen JA. Late occurrence of PML in a patient treated for lymphoma with immunomodulatory chemotherapies, bendamustine, rituximab, and ibritumomab tiuxetan. Case Rep Neurol Med. 2015;2015:892047.
15. Lejniece S, Murovska M, Chapenko S, Breiksa B, Jaunmuktane Z, Feldmane L, et al. Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient. Exp Oncol. 2011;33:239-41.